

**Disclaimer:** The content below is for communication purpose only. Our company and its affiliates do not guarantee to anybody that the information below is complete and up-to-date. Our company and its affiliates do not accept any responsibility for any decision made as a result of relying on the information contained herein.


More Details on: [www.microport.com.cn](http://www.microport.com.cn)

Email: [ir@microport.com](mailto:ir@microport.com)  
Tel (021) 38954600  
Fax (021) 50801305

## Clinical Application Research of WILLIS™ Obtained the First Class Award in Science and Technology Progress

On May 18<sup>th</sup>, the clinical application of <Cerebral aneurysms and its related vascular MRA imaging and key technologies of interventional treatment>, which based on clinical research of WILLIS™ intracranial graft stent obtained the First Class Award of Science and Technology Progress issued by the Ministry of Education. MicroPort, as one of the co-sponsors for the research project, won the award together with Shanghai Sixth People's Hospital.

WILLIS™ intracranial stent is the first graft stent product that is indicated for the treatment of intracranial aneurysms. WILLIS™ intracranial graft stent can isolate and make occlusion of the aneurysm, as well as reserve the aneurysm artery patency and restore normal blood flow in the lesions area. WILLIS™ clinical trials have successfully achieved its research hypothesis: six months' total occlusive ratio of aneurysm was superior to the method of coil embolization.



## The 2<sup>nd</sup> Board Meeting of MicroPort 2012 Held Successfully

The 2nd Board Meeting of MicroPort Scientific Corporation was successfully held in Ridge Vineyard, California USA from May 30<sup>th</sup> to May 31<sup>th</sup>. MicroPort's executive directors, non-executive directors and independent non-executive directors attended the meeting.

## The Oriental Congress of Cardiology 2012 Held in Shanghai

The 6<sup>th</sup> Oriental Congress of Cardiology (OCC 2012) was held at Shanghai International Convention Center from May 25 to 27, 2012.

On May 23, MicroPort organized the "2012 Cardiac Intervention Device and Clinical Technology Development Summit" in Ritz Carton Hotel, Shanghai. MicroPort invited many national renowned experts in cardiac intervention field, including academician Junbo Ge from Zhong Shan Hospital Fudan University who is also the chairman of the OCC 2012. These experts have proposed some significant suggestions on the future development of MicroPort.

On May 26, MicroPort organized a satellite meeting on the theme of 2-year follow-up of Firebird2 clinical studies. The chief doctor Zhangfeng presented the results in regard to the 2-year follow-up clinical studies named "FOCUS". The follow-up rate reached 95.7%. Among 4867 enrolled patients, the All Death

ratio was 2.51%. The MACE (Major Adverse Cardiac Events) was 5.2% which includes 1.52% of cardiac-related death, Q-wave myocardial infarction 1.23%, and non-Q-wave myocardial infarction 2.03%. The incidence of TVR and thrombosis was 1.58% and 1.5% respectively. The optimized vessel conformability, low incidence of restenosis and thrombosis has been recognized by many experts, and all of these results have further validated the efficacy and safety of Firebird2.

## MicroPort Employee Appreciation & Recognition Day and Celebration of Company 14<sup>th</sup> Anniversary

MicroPort Employee Appreciation & Recognition Day, which also marked the 14<sup>th</sup> Anniversary of MicroPort, was celebrated on May 15. Early in the morning, all of the top management waited in the company's main entrance hall and warmly greeted every employee with a gift book <Life without Limits>. By noon, a lavish buffet was served in the dining hall of the company. And abundant activities were also held in the subsidiaries of MicroPort. The newly designed MicroPort Chinese website was officially launched on the same day.



## Euro PCR 2012

From May 15 to May 18, Euro PCR 2012, which aimed at achieving ideal treatment for patients, was successfully held in Paris. It had a great significance in developing new technology for the treatment of interventional cardiology. All the experts in the related fields were invited; including surgeons, doctors specialized in interventional cardiology, radiology, angiology and some manufactures. On May 18, 4 MicroPort's stents (FireHawk) were used in the on-sight surgeries conducted by Fuwai Hospital, which attracted a great amount of attention and discussion.



## The 13<sup>th</sup> Leadership Exchanging Meeting of SFIC Held Successfully

The 13<sup>th</sup> Leadership Exchanging Meeting of SFIC (Shanghai Federation of Industry and Commerce) was successfully held at Shanghai Exhibition Center from May 6<sup>th</sup> to 7<sup>th</sup>. Dr. Zhaohua Chang, executive director and chairman of MicroPort was elected as vice chairman of the SFIC.